Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Elamipretide→

Elamipretide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
736992-21-5
Molecular formula
C32H49N9O5
Molecular weight
639.79 g/mol
Drug class
Mitochondria-targeted tetrapeptidecardiolipin-binding mitochondrial modulator
Mechanism of action
Binds cardiolipin in the inner mitochondrial membrane and localises to the inner mitochondrial membrane, where it is intended to improve mitochondrial structure and function. The clinical mechanism underlying increased muscle strength in Barth syndrome is not fully established.
Indications / reported uses
  • To improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg under the US FDA FORZINITY accelerated-approval indication (September 19 2025)

Sources: US DailyMed — FORZINITY (elamipretide), updated December 10 2025 · US FDA — FORZINITY accelerated approval · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Mitochondria-targeted tetrapeptide; cardiolipin-binding mitochondrial modulator

Mechanism of action

Binds cardiolipin in the inner mitochondrial membrane and localises to the inner mitochondrial membrane, where it is intended to improve mitochondrial structure and function. The clinical mechanism underlying increased muscle strength in Barth syndrome is not fully established.

General use cases

  • To improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg under the US FDA FORZINITY accelerated-approval indication (September 19 2025)

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Elamipretide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Elamipretide Permitted Daily Exposure (PDE) report (the Elamipretide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Elamipretide Occupational Exposure Limit (OEL) report (the Elamipretide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.